Upper Tract Urothelial Carcinoma: A Narrative Review of Current Surveillance Strategies for Non-Metastatic Disease

被引:3
|
作者
Klemm, Jakob [1 ,2 ]
Bekku, Kensuke [2 ,3 ]
Abufaraj, Mohammad [2 ,4 ]
Laukhtina, Ekaterina [2 ,5 ]
Matsukawa, Akihiro [2 ,6 ]
Parizi, Mehdi Kardoust [2 ]
Karakiewicz, Pierre I. [7 ]
Shariat, Shahrokh F. [2 ,5 ,8 ,9 ,10 ,11 ,12 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Urol, D-20251 Hamburg, Germany
[2] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, A-1090 Vienna, Austria
[3] Okayama Univ, Dept Urol Dent & Pharmaceut Sci, Grad Sch Med, Okayama 7008525, Japan
[4] Jordan Univ Hosp, Univ Jordan, Dept Special Surg, Div Urol, Amman 11733, Jordan
[5] Sechenov Univ, Inst Urol & Reprod Hlth, Moscow 119991, Russia
[6] Jikei Univ Sch Med, Dept Urol, Tokyo 1058461, Japan
[7] Univ Montreal, Canc Prognost & Hlth Outcomes Unit, Hlth Ctr, Montreal, PQ H2X 3E4, Canada
[8] Al Ahliyya Amman Univ, Hourani Ctr Appl Sci Res, Amman 11942, Jordan
[9] Karl Landsteiner Inst Urol & Androl, A-1090 Vienna, Austria
[10] Weill Cornell Med Coll, Dept Urol, New York, NY 10065 USA
[11] Univ Texas Southwestern, Dept Urol, Dallas, TX 75390 USA
[12] Charles Univ Prague, Fac Med 2, Dept Urol, Prague 25250, Czech Republic
关键词
upper tract urothelial carcinoma; urothelial carcinoma; surveillance; follow-up; UPPER URINARY-TRACT; KIDNEY-SPARING SURGERY; RADICAL NEPHROURETERECTOMY; SEGMENTAL URETERECTOMY; ONCOLOGIC OUTCOMES; INTRAVESICAL RECURRENCE; CONDITIONAL SURVIVAL; RISK STRATIFICATION; RENAL-FUNCTION; ASSOCIATION;
D O I
10.3390/cancers16010044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Upper tract urinary carcinoma (UTUC) is a rare type of cancer affecting the urinary system. Patients with UTUC often undergo surgeries like kidney-sparing surgery or radical nephroureterectomy. However, even after treatment, there remains a risk of the cancer recurring in different parts of the body. This narrative review aims to better understand the frequency and locations of such recurrences, which is crucial for effectively monitoring patients after their initial treatment. Currently, there is limited information on the optimal methods for tracking patients post-surgery, and on how early detection of cancer, before the appearance of symptoms, might improve health outcomes. This article presents the most important current guideline recommendations and elucidates the evidence behind them. Exploring new imaging technologies and improving methods for assessing patient risk, can potentially lead to more personalized and effective monitoring plans in the near future.Abstract Non-metastatic upper urinary tract carcinoma (UTUC) is a comparatively rare condition, typically managed with either kidney-sparing surgery (KSS) or radical nephroureterectomy (RNU). Irrespective of the chosen therapeutic modality, patients with UTUC remain at risk of recurrence in the bladder; in patients treated with KSS, the risk of recurrence is high in the remnant ipsilateral upper tract system but there is a low but existent risk in the contralateral system as well as in the chest and in the abdomen/pelvis. For patients treated with RNU for high-risk UTUC, the risk of recurrence in the chest, abdomen, and pelvis, as well as the contralateral UT, depends on the tumor stage, grade, and nodal status. Hence, implementing a risk-stratified, location-specific follow-up is indicated to ensure timely detection of cancer recurrence. However, there are no data on the type and frequency/schedule of follow-up or on the impact of the recurrence type and site on outcomes; indeed, it is not well known whether imaging-detected asymptomatic recurrences confer a better outcome than recurrences detected due to symptoms/signs. Novel imaging techniques and more precise risk stratification methods based on time-dependent probabilistic events hold significant promise for making a cost-efficient individualized, patient-centered, outcomes-oriented follow-up strategy possible. We show and discuss the follow-up protocols of the major urologic societies.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma
    Locke, Jennifer A.
    Hamidizadeh, Reza
    Kassouf, Wassim
    Rendon, Ricardo A.
    Bell, David
    Izawa, Jonathan
    Chin, Joseph
    Kapoor, Anil
    Shayegen, Bobby
    Lattouf, Jean-Baptiste
    Saad, Fred
    Lacombe, Louis
    Fradet, Yves
    Fairey, Adrien S.
    Jacobson, Niels-Eric
    Drachenberg, Darrel E.
    Cagiannos, Ilias
    So, Alan I.
    Black, Peter C.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2018, 12 (08): : 243 - 251
  • [42] Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma
    Kapoor, Anil
    Allard, Christopher B.
    Black, Peter
    Kassouf, Wassim
    Morash, Christopher
    Rendon, Ricardo
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2013, 7 (9-10): : 306 - 311
  • [43] Gold standard nephroureterectomy, chemoprophylaxis and surveillance in upper tract urothelial carcinoma
    Basile, Giuseppe
    Bandini, Marco
    Li, Roger
    Poch, Michael A.
    Necchi, Andrea
    Spiess, Philippe E.
    CURRENT OPINION IN UROLOGY, 2025, 35 (01) : 75 - 82
  • [44] The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance?
    Syed, Jamil
    Nguyen, Kevin
    Javier-Desloges, Juan
    Leapman, Michael
    Raman, Jay D.
    Shuch, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [45] Comparison of clinicopathological features in metastatic upper tract urothelial carcinoma and urothelial bladder cancer
    Xie, Jing
    Zhang, Xue-Bin
    Wen, Jin
    Zhang, Yu-Shi
    Li, Han-Zhong
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2016, 48 (04) : 481 - 487
  • [46] Comparison of clinicopathological features in metastatic upper tract urothelial carcinoma and urothelial bladder cancer
    Jing Xie
    Xue-Bin Zhang
    Jin Wen
    Yu-Shi Zhang
    Han-Zhong Li
    International Urology and Nephrology, 2016, 48 : 481 - 487
  • [47] Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease
    Kyle M. Rose
    Heather L. Huelster
    Joshua J. Meeks
    Bishoy M. Faltas
    Guru P. Sonpavde
    Seth P. Lerner
    Jeffrey S. Ross
    Philippe E. Spiess
    G. Daniel Grass
    Rohit K. Jain
    Ashish M. Kamat
    Aram Vosoughi
    Liang Wang
    Xuefeng Wang
    Roger Li
    Nature Reviews Urology, 2023, 20 : 452 - 452
  • [48] Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder
    Laukhtina, E.
    Boehm, A.
    Peyronnet, B.
    Bravi, C. A.
    Da Costa, Batista J.
    Soria, F.
    D'andrea, D.
    Quhal, F.
    Rajwa, P.
    Motlagh, Sari R.
    Yanagisawa, T.
    Koenig, F.
    Pallauf, M.
    Mostafaei, H.
    Kawada, T.
    Ingels, A.
    Verhoest, G.
    D'Hondt, F.
    Mottrie, A.
    Van Poppel, H.
    De La Taille, A.
    Bruyere, F.
    Bensalah, K.
    Shariat, S. F.
    Pradere, B.
    EUROPEAN UROLOGY, 2023, 83
  • [49] Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma
    De Lorenzis, Elisa
    Albo, Giancarlo
    Longo, Fabrizio
    Bebi, Carolina
    Boeri, Luca
    Montanari, Emanuele
    GENES, 2021, 12 (03) : 1 - 19
  • [50] Optimal Management of Upper Tract Urothelial Carcinoma: Current Perspectives
    Leow, Jeffrey J.
    Liu, Zhenbang
    Tan, Teck Wei
    Lee, Yee Mun
    Yeo, Eu Kiang
    Chong, Yew-Lam
    ONCOTARGETS AND THERAPY, 2020, 13 : 1 - 14